INTRODUCTION
Cardiovascular disease (CVD) is 1 of the most frequent causes of death in developing and developed nations. In 2011, the World Health Organisation (WHO) estimated annual deaths from CVD at more than 17 million, of which 7.6 million were due to ischaemic heart disease resulting in an acute myocardial infarction (AMI). (1) In South Africa, CVD is the second most prevalent cause of death after HIV-associated disease, and accounts for up to 40% of deaths among adults. (2) AMI typically follows the rupture of an atherosclerotic plaque, with resultant platelet aggregation and thrombotic occlusion.
Modifiable risk factors for atherosclerosis include hyperlipidaemia, smoking, hypertension, diabetes mellitus (DM), abdominal obesity and physical inactivity. (3, 4) These risk factors synergistically increase the overall risk of development of an AMI, regardless of gender or age. (5) Increased levels of lowdensity lipoprotein cholesterol (LDL-C) and decreased levels of high-density lipoprotein cholesterol (HDL-C) play a pivotal role in atherogenesis and are associated with a higher risk of development of coronary artery disease (CAD). (6) (7) (8) Statin therapy has been implemented in both primary and secondary prevention of CAD. (9) Statin therapy following an AMI has been shown to be effective in reducing mortality by at Volume 15 Number 3
SUBJECTS AND METHODS
The study site is a 350-bed regional hospital in Durban, KwaZulu-Natal, which services the communities of Phoenix, Data on prevalence of risk factors were also documented. 
RESULTS
During the study period, 154 subjects presented to the emergency department with a suspected diagnosis of AMI. Twenty eight were excluded, leaving a final sample of 126 subjects ( Figure 1 ). The demographic profile, clinical presentation and risk profile of the subjects is shown in We noted a high prevalence of combined and mixed hyperlipidaemia ( Figure 2 ). The distribution of values for each lipoprotein is shown in Table II . There were no statistically significant differences in lipid profile between males and females.
Eighty subjects had received prior therapy with either simvastatin or atorvastatin (Table III) . No subject was reported as having used fibrates or other lipid-lowering agents. We noted a significantly lower LDL-C and lower incidence of STEMI in those who had received statin therapy. There were no significant differences in other lipid parameters between these 2 groups. There was no significant difference in lipid levels between diabetic and non-diabetic subjects, and no significant correlation between lipid levels and the extent of diabetic control (Table IV) . Poor lipid control was seen in subjects with both controlled and poorly controlled DM, as assessed by HbA 1c levels. Diabetic patients were significantly more likely to demonstrate an NSTEMI.
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The distribution of LDL-C values is shown in Figure 3 (Table V) . No lipid parameter differed significantly between those subjects with a previous AMI and those with a first AMI (data not shown).
There was no significant difference in the number of subjects with and without a previous AMI whose LDL-C value was below the target level recommended for their risk category, as defined above: 4 of 31 (12.9%) vs. 19 of 95 (20.0%, p=0.44).
There was also no significant difference in the number of diabetic subjects with and without previous AMI with an optimal glycated haemoglobin value: 9 of 24 (37.5%) vs. 22 of 71 (31.0%, p=0.62).
DISCUSSION
Nearly all subjects were of Indian descent. Though this is in keeping with previous studies showing South African Indian subjects to be a high-risk population for CAD, with a high prevalence of hyperlipidaemia, (10) (11) (12) the prevalence we found is likely to have been influenced by the surrounding population of our hospital, which serves an area with a large Indian population. Most subjects in this study were shown to have hyperlipidaemia, with 63.5% having a pre-existing diagnosis of hyperlipidaemia and 23.8% subjects a new diagnosis (Table 1) .
Increased TC, LDL-C and non-HDL-C levels, with decreased levels of HDL-C, were seen in most subjects in this studyindicating poor lipid control. Elevated non-HDL-C may be a risk indicator for CVD and the mean level in our study population was 4.43, with the target value being less than 2.6mmol/L. (13) A large number of subjects previously diagnosed with hyperlipidaemia had poorly controlled lipid levels, despite being on statin therapy (Table V) Atherosclerotic CVD is associated with a number of risk factors. Hyperlipidaemia, hypertension and cigarette smoking together, are associated with a 7-fold increase risk for ACS. (14) The mean number of risk factors in our subjects was 3.45, equating to a high-risk population for CAD. In other local studies, Masina, et al. reported smoking, hypertension and DM as being the most prevalent risk factors for CAD in the African community of South Africa, while Chetty and Ross, et al. reported smoking, DM and family history of CAD as prominent cardiovascular risk factors in the Indian population. (15, 16) In our study, hyperlipidaemia was the most prevalent risk factor, with 87.3% of all cases having abnormal lipid profiles. We found no gender predisposition for hyperlipidaemia. Hypertension and DM were also frequently encountered. Despite an extensive national anti-smoking programme in place since 1993, including a complete ban on tobacco advertising and the inclusion of health warnings on packaging, 71.8% of males in our study had a smoking history.
Most of our subjects were male. It is known that there is a gender difference in the rates of CAD, with men having a 40%
higher risk of dying from any form of CAD than women. (17) Smoking was also found to be more prevalent in males than females -resulting in men having an added risk factor for CVD. (18, 19) Additional determinants may be differences in exposure to other risk factors and the cardio-protective effects of oestrogen in the female sub-population. A reduction in oestrogen production in post-menopausal women changes the lipid metabolism toward a more atherogenic form by increasing TC, LDL-cholesterol and triglyceride level, with a reduction in HDL cholesterol. (20) In our study, however, females presented with premature CAD more frequently than males, and a possible explanation for this lies in the observation that female subjects had a higher prevalence of other risk factors, including hypertension and DM, as has also been shown in the Phoenix Lifestyle project.
The high incidence of DM in our subjects may be a major cause of secondary dyslipidaemia. statin therapy itself, the incidence of this is thought to be extremely low, and the association between statin use and DM has not been shown to be causal. (26, 27) We therefore believe that the high prevalence of DM in our study is a true reflection of its actual prevalence, and is not artificially increased by statin therapy.
LIMITATIONS
This is a retrospective chart audit at a single centre, with no control group. Our findings may be strengthened by expanding the study to include a larger population at multiple sites. The study focused on a number of risk factors, particularly hyperlipidaemia, but was not designed to provide data in detail for other risk factors such as obesity, hypertension, quantification of smoking exposure, and treatment compliance. We were unable to perform accurate risk stratification owing to lack of data.
Angiography is not available at this hospital, and we were 
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better in those with a previous AMI than in those with a first AMI, support our view that, in these subjects, secondary prophylaxis has not resulted in optimal metabolic outcomes.
RECOMMENDATIONS
Our findings support the need for the current national screening programme for DM and hypertension and we suggest that this be expanded to include screening for hyperlipidaemia.
Strengthening primary healthcare to ensure adequate primary prevention of IHD by effective control of modifiable risk factors for CAD needs urgent attention as we have demonstrated this to be a problem in the subjects studied. Once identified, subjects need to be commenced on effective treatment, and be treated to target. In addition to pharmacotherapy, interventions are required to improve drug availability, adherence to medication, and to bring about lifestyle modifications including appropriate diet, regular exercise and smoking cessation.
Though use of a combined pill (the "polypill") consisting of aspirin, statin and antihypertensive has been reported as being associated with improved compliance, (29) (30) (31) (32) (33) a Cochrane review has suggested that the evidence is not as yet conclusive, and that further studies are necessary to establish its utility. (34) Many newer lipid-lowering agents are under development and a few, such as the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, are now approved for use elsewhere, though not in South Africa. (35) Availability of alternate treatment for subjects unable to tolerate first line statin therapy may improve lipid control in these subjects.
